On April 11, Catalyst Biosciences, a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, reached a key milestone towards starting human trials withÂ completion of the CB 2679d/ISU304 toxicology studies. Their press release can be read in fullÂ here.
Aptevo’s Ixinity, previously approved for use in people over the age of 12, just received approval for use in children under 12, per their ongoing phase 3 trial. Read the full press release here.
Spark Therapeutics issued a press release on updated preliminary data from 10 infused participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for hemophilia B. The data isÂ being presented at Hemostastis &Â Thrombosis Research Society (HTRS) this week.The press release can be read in full here.